SoftOx Solutions

SOFTX

NO0010811961

Biotechnology & Medical Research

Market Closed - Oslo Bors Other stock markets 08:15:00 07/06/2024 pm IST			5-day change	1st Jan Change
0.21 ^NOK	+23.53%		+137.02%	-93.52%

18/04	Transcript : SoftOx Solutions AS - Special Call
20/03	SoftOx Solutions AS Reports Earnings Results for the Full Year Ended December 31, 2023	CI

SoftOx Solutions AS First half year 2023 report

September 26, 2023 at 10:33 am IST

Please find attached the first half year report 2023 for SoftOx Solutions AS

Click here for more information

Latest news about SoftOx Solutions

Transcript : SoftOx Solutions AS - Special Call	18/04
SoftOx Solutions AS Reports Earnings Results for the Full Year Ended December 31, 2023	20/03	CI
SoftOx Solutions AS Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	20/03	CI
SoftOx Solutions Seeks Extension of NOK40 Million Convertible Loan; Shares Jump	16/01	MT
SoftOx Solutions AS announced that it expects to receive NOK 40 million in funding	11/01	CI
SoftOx Solutions AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	01/11	CI
SoftOx Solutions AS Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	26/23/26	CI
SoftOx Solutions Faces Penalty from Oslo Børs	18/23/18	MT
SoftOx Solutions AS Reports Earnings Results for the First Quarter Ended March 31, 2023	21/23/21	CI
SoftOx Solutions AS announced that it has received NOK 15 million in funding	09/23/09	CI
Oslo Børs Places Seven Issuers in Penalty Bench over Public Disclosure Rule Violations	02/23/02	MT
SoftOx Solutions Launches Temporary Layoffs Amid Restructuring; Shares Down 29%	27/23/27	MT
Softox Solutions AS Announces Resignation of Kari Myren from the Board	24/23/24	CI
SoftOx Solutions AS Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	15/23/15	CI
Softox Solutions Announces Signing of the Final Grant Agreement for the Counteract Consortium	09/23/09	CI
SoftOx Solutions Appoints Interim CEO, New CFO	20/22/20	MT
SoftOx Solutions AS Appoints Christian Harstad as the Interim Chief Executive Officer	20/22/20	CI
SoftOx Solutions AS Announces Chief Financial Officer Changes	20/22/20	CI
Softox Solutions AS Announces Final Report Reaffirms Positive Top Line Phase 1 Results for Softox Biofilm Eradicator	15/22/15	CI
SoftOx Solutions AS Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	26/22/26	CI
Softox Solutions Receives Swedish Approval For Disinfect Product	19/22/19	MT
Softox Solutions AS Announces Approval from the Swedish Chemicals Agency on Disinfection Products	19/22/19	CI
SoftOx Solutions Signs $2 Million Convertible Loan Deal, Secures Refinancing	11/22/11	MT
SoftOx Solutions AS announced that it expects to receive NOK 40 million in funding from Aubert Invest AS, Pro AS, Almhaug Bolig AS and other investors	11/22/11	CI
SoftOx Solutions AS Announces Positive Top Line Phase 1 Results for Softox Biofilm Eradicator	04/22/04	CI

SoftOx Solutions AS is a Norway-based medtech and biotech company, that develops products to help fight infections from viruses, biofilm resistance and antimicrobial resistance. It is a developer of infection control solutions for disinfection, wound care and the respiratory tract. The current business segments can be divided into: Wounds, Disinfection and Respiratory. SoftOx Solutions is engaged in the development of a range of products that can be classified as either medical devices or medicinal products for human use. SoftOxâs product portfolio includes such products as SafeDes+, a hand disinfectant for irritated, compromised and eczematous skin. The Company has several subsidiaries, including SoftOx Disinfection AS, SoftOx Defense Solutions AS and SoftOx Denmark AS.

Sector

Biotechnology & Medical Research

Calendar

04/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SOFTOX SOLUTIONS	-93.52%	10.14M
VERTEX PHARMACEUTICALS INCORPORATED	+18.72%	125B
REGENERON PHARMACEUTICALS, INC.	+14.19%	108B
BIONTECH SE	-4.93%	24.21B
ARGENX SE	+3.23%	22.78B
GENMAB A/S	-10.44%	17.96B
WUXI APPTEC CO., LTD.	-41.74%	16.43B
BEIGENE, LTD.	-13.31%	16.37B
NEUROCRINE BIOSCIENCES, INC.	+2.44%	13.58B
SAREPTA THERAPEUTICS, INC.	+27.89%	11.66B